A Novel Chaperone-Based Cancer Vaccination Enhances Immunotherapeutic Responsiveness Through T Cell Amplification and Tumor Immune Remodeling
Given the safety and T cell stimulation profiles of the chaperone-antigen complex vaccine already established in our recent clinical trial, this new generation of chaperone cargo, capable of delivering both antigenic targets and pathogen-associated immunoactivating signals simultaneously, represents a promising strategy to potentially improve the low response rates in patients receiving immune checkpoint inhibitors.
Authors
- Xueqian Cheng (ORCID: https://orcid.org/0000-0001-8454-1071)
- Jinyang Cai (ORCID: https://orcid.org/0000-0002-7385-8281)
- John R. Subjeck
- Masoud H. Manjili (ORCID: https://orcid.org/0000-0001-7511-2953)
- Elizabeth A. Repasky (ORCID: https://orcid.org/0000-0002-9554-4152)
- Chunqing Guo (ORCID: https://orcid.org/0000-0002-3148-8542)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-7260-209X)
- Wenjie Liu (ORCID: https://orcid.org/0000-0002-4281-442X)
- Xiangyang Wang (ORCID: https://orcid.org/0000-0002-6504-2661)
- Xiaofei Yu (ORCID: https://orcid.org/0000-0002-0188-6654)
- Syed Shah (ORCID: https://orcid.org/0009-0003-4083-0535)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Virginia Commonwealth University (US)
- Veterans Health Administration (US)
- Hunter Holmes McGuire VA Medical Center (US)
Publication Details
- Journal
- Vaccines
- Published
- 2025-10-25
- DOI
- https://doi.org/10.3390/vaccines13111096
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00